

Navneet S Majhail

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/996934/publications.pdf>

Version: 2024-02-01

133
papers

4,343
citations

101543

36
h-index

118850

62
g-index

135
all docs

135
docs citations

135
times ranked

4753
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 335-343.	1.3	5
2	Community health status and long-term outcomes in 1-year survivors of autologous and allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 671-673.	2.4	2
3	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 310-320.	1.2	11
4	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 1031-1033.	2.4	1
5	Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2679-2685.	1.3	3
6	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	4.1	12
7	Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 222-229.	1.2	27
8	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	1.4	34
9	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	1.2	45
10	Secular trends of Blood stream infections in allogeneic hematopoietic cell transplant recipients 72 hours prior to death. <i>Transplant Infectious Disease</i> , 2021, 23, e13631.	1.7	1
11	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. <i>JCI Insight</i> , 2021, 6, .	5.0	12
12	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 917.e1-917.e9.	1.2	3
13	Image-guided volumetric-modulated arc therapy of total body irradiation: An efficient workflow from simulation to delivery. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 169-177.	1.9	13
14	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1344-1352.	1.3	7
15	Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	0
16	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. <i>Blood</i> , 2021, 138, 2781-2798.	1.4	27
17	Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 2899-2899.	1.4	1
18	Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (>=60 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors. <i>Blood</i> , 2021, 138, 4123-4123.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Community Health Status and Long-Term Outcomes in 1-Year Survivors of Autologous and Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 422-422.	1.4	0
20	Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: Secondary Analysis of Two Randomized Controlled Trials on Survivorship Care Plans. <i>Blood</i> , 2021, 138, 431-431.	1.4	0
21	Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomic. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 275-280.	2.5	19
22	Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 262-271.	2.0	17
23	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 160-165.	0.9	8
24	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650.	4.1	28
25	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 32-39.	0.9	7
26	Primary Care Physician Perspectives on Caring for Adult Survivors of Hematologic Malignancies and Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 70-77.	0.4	10
27	Severity of acute gastrointestinal graft-versus-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13217.	1.7	10
28	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. <i>Bone Marrow Transplantation</i> , 2020, 55, 906-917.	2.4	33
29	Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1505-1510.	2.0	11
30	Not So Young at Heart. <i>JACC: CardioOncology</i> , 2020, 2, 472-474.	4.0	0
31	Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 14, 318-326.	0.9	7
32	To D or not to D: vitamin D in hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 2060-2070.	2.4	6
33	Patient-reported outcomes in acute graft-versus-host disease: optimizing patient care and clinical trial endpoints. <i>Bone Marrow Transplantation</i> , 2020, 55, 1533-1539.	2.4	4
34	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. <i>American Journal of Hematology</i> , 2020, 95, 672-690.	4.1	22
35	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
36	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17

#	ARTICLE	IF	CITATIONS
37	Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2335-2345.	2.0	28
38	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
39	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. <i>Blood</i> , 2020, 136, 38-39.	1.4	2
40	Comparison of Outcomes and Quality-of-Life Measures Following Haploidentical Vs. Matched Related/Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
41	Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience. <i>Blood</i> , 2020, 136, 26-27.	1.4	0
42	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. <i>Blood</i> , 2020, 136, 21-21.	1.4	0
43	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e344-e351.	2.0	59
44	Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement system-global health (PROMIS-GH) in a real-world population. <i>Leukemia and Lymphoma</i> , 2019, 60, 3544-3551.	1.3	4
45	Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2522-2526.	2.0	4
46	Penicillin allergy skin testing as an antibiotic stewardship intervention reduces alternative antibiotic exposures in hematopoietic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13175.	1.7	12
47	Progression with clinical features is associated with worse subsequent survival in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 439-445.	4.1	12
48	Psychosocial Assessment of Candidates for Transplant (PACT) as a tool for psychological and social evaluation of allogeneic hematopoietic cell transplantation recipients. <i>Bone Marrow Transplantation</i> , 2019, 54, 1443-1452.	2.4	21
49	High-dose chemotherapy and autologous transplantation for testicular germ cell tumors. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e47.	0.9	2
50	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2086-2090.	2.0	42
51	Early infectious complications after autologous hematopoietic cell transplantation for multiple myeloma. <i>Transplant Infectious Disease</i> , 2019, 21, e13114.	1.7	19
52	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 845-854.	2.0	69
53	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. <i>Bone Marrow Transplantation</i> , 2019, 54, 1553-1561.	2.4	6
54	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2732-2737.	5.2	9

#	ARTICLE	IF	CITATIONS
55	Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 664-672.	2.0	3
56	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. <i>Haematologica</i> , 2019, 104, 1084-1092.	3.5	46
57	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2019, 54, 1281-1286.	2.4	24
58	Effect of bone marrow CD34+ cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 775-781.	2.4	14
59	Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 562-569.	2.0	16
60	Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e155-e162.	2.0	56
61	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.	2.0	20
62	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1107-1115.	2.0	9
63	Twitter Use in the Hematopoietic Cell Transplantation Community. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 53-58.	2.3	12
64	Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1546-1553.	2.0	40
65	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1029-1034.	2.0	19
66	Community Risk Score for Evaluating Health Care Disparities in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 877-879.	2.0	9
67	ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1119-1124.	2.0	33
68	Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1278-1287.	2.4	25
69	Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 4-12.	2.0	6
70	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
71	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2018, 59, 1195-1201.	1.3	11
72	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e95-e102.	0.4	6

#	ARTICLE	IF	CITATIONS
73	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large cell lymphoma. <i>Cancer</i> , 2018, 124, 816-825.	4.1	44
74	Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. <i>Journal of Clinical Apheresis</i> , 2018, 33, 303-309.	1.3	6
75	Unique Challenges of Hematopoietic Cell Transplantation in Adolescent and Young Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e11-e19.	2.0	21
76	Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 576-580.	2.3	5
77	Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2145-2151.	2.0	14
78	Infectious complications in multiple myeloma (MM) patients receiving autologous hematopoietic cell transplantation (AutoHCT) in the contemporary era.. <i>Journal of Clinical Oncology</i> , 2018, 36, e20003-e20003.	1.6	0
79	Venous Thromboembolism with Contemporary Lenalidomide-Based Regimens and Adequate Thromboprophylaxis in Newly Diagnosed Multiple Myeloma: A Systemic Review and Meta-Analysis. <i>Blood</i> , 2018, 132, 4835-4835.	1.4	0
80	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2075-2075.	1.4	0
81	Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1899-1899.	1.4	3
82	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. <i>Blood</i> , 2018, 132, 371-371.	1.4	0
83	Psychosocial Evaluation in Allogeneic Hematopoietic Cell Transplantation Recipients (Allo HCT): Psychosocial Assessment of Candidates for Transplant (PACT) As a Tool to Identify High-Risk Patients and Its Association with Transplant Outcomes. <i>Blood</i> , 2018, 132, 3600-3600.	1.4	0
84	Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400%cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 776-781.	2.0	3
85	Race colors transplantation utilization for multiple myeloma. <i>Cancer</i> , 2017, 123, 3005-3006.	4.1	0
86	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
87	Impact of social media for the hematologist/oncologist. <i>Seminars in Hematology</i> , 2017, 54, 193-197.	3.4	11
88	Long-term complications after hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 220-227.	0.9	116
89	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 6-9.	2.0	49
90	National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 717-725.	2.0	40

#	ARTICLE	IF	CITATIONS
91	Patient-centered care coordination in hematopoietic cell transplantation. <i>Blood Advances</i> , 2017, 1, 1617-1627.	5.2	28
92	Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation: Risk Stratification and Outcomes. <i>Open Forum Infectious Diseases</i> , 2017, 4, S727-S728.	0.9	0
93	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial. <i>Blood</i> , 2017, 130, 847-847.	1.4	8
94	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1493-1503.	2.0	55
95	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Timesâ€“Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1588-1595.	2.0	9
96	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1915-1925.	2.0	130
97	Supportive care in alternative donor transplantation. <i>Seminars in Hematology</i> , 2016, 53, 129-135.	3.4	3
98	Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1141-1144.	2.0	9
99	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 4666-4666.	1.4	0
100	Social Media and the Practicing Hematologist: Twitter 101 for the Busy Healthcare Provider. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 405-412.	2.3	46
101	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1308-1314.	2.0	45
102	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104
103	Guidelines for Defining and Implementing Standard Episode of Care for Hematopoietic Stem Cell Transplantation within the Context of Clinical Trials. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 583-588.	2.0	18
104	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838.	2.0	12
105	Conditioning regimens for refractory acute myeloid leukaemia. <i>Lancet Haematology</i> , 2015, 2, e354-e355.	4.6	0
106	Optimizing Quality and Efficiency of Healthcare Delivery in Hematopoietic Cell Transplantation. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 199-204.	2.3	11
107	Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent Era. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 142-150.	2.0	66
108	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49

#	ARTICLE	IF	CITATIONS
109	Association of Socioeconomic Status (SES) with Outcomes of Autologous Hematopoietic Cell Transplantation (ASCT) for Lymphoma. <i>Blood</i> , 2015, 126, 4494-4494.	1.4	0
110	Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1819-1827.	2.0	43
111	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
112	Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1116-1123.	2.0	104
113	Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2013, 31, 2437-2449.	1.6	223
114	Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 348-371.	2.0	324
115	Allogeneic Transplant Physician and Center Capacity in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 956-961.	2.0	43
116	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011, 117, 4651-4657.	1.4	319
117	Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. <i>Haematologica</i> , 2011, 96, 1528-1535.	3.5	48
118	To cry or not to cry: physicians and emotions at the bedside. <i>Minnesota Medicine</i> , 2011, 94, 40-2.	0.1	1
119	Access to hematopoietic stem cell transplantation. <i>Cancer</i> , 2010, 116, 3469-3476.	4.1	124
120	The National Marrow Donor Program's Symposium on Patient Advocacy in Cellular Transplantation Therapy: Addressing Barriers to Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 147-156.	2.0	15
121	Access to Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1070-1075.	2.0	85
122	Late complications in blood and marrow transplant survivors. <i>Minnesota Medicine</i> , 2010, 93, 45-9.	0.1	15
123	The Homecoming. <i>Journal of Clinical Oncology</i> , 2009, 27, 5857-5858.	1.6	1
124	Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2009, 147, 129-139.	2.5	59
125	Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1543-1554.	2.0	135
126	Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 282-289.	2.0	119

#	ARTICLE	IF	CITATIONS
127	Late Effects in Survivors of Hodgkin and Non-Hodgkin Lymphoma Treated with Autologous Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1153-1159.	2.0	99
128	Diffuse Alveolar Hemorrhage and Infection-Associated Alveolar Hemorrhage following Hematopoietic Stem Cell Transplantation: Related and High-Risk Clinical Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1038-1046.	2.0	130
129	Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1065-1072.	2.0	171
130	Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. <i>Blood</i> , 2006, 107, 3804-3807.	1.4	103
131	Adjuvant Subcutaneous Interleukin-2 in Patients with Resected Renal Cell Carcinoma: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 50-56.	1.9	9
132	Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomas. <i>Psychophysiology</i> , 2005, 4, 252-9.	1.1	4
133	Acute leukemia with a very high leukocyte count: confronting a medical emergency.. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 633-637.	1.3	59